• 제목/요약/키워드: Myelodysplastic syndrome(MDS)

검색결과 18건 처리시간 0.034초

Kostmann 증후군과 골수이형성 증후군 환아의 증례보고 (KOSTMANN SYNDROME AND MYELODYSPLASTIC SYNDROME WITH DENTAL PROBLEM : A CASE REPORT)

  • 현홍근
    • 대한장애인치과학회지
    • /
    • 제4권1호
    • /
    • pp.32-36
    • /
    • 2008
  • 본 증례에서 나타난 Kostmann 증후군 및 MDS의 치과적 소견을 정리해 보면, 전반적인 치주염(GPP), 고도의 치조골 소실 및 치아동요도, 협점막의 궤양, 편도염, 구강내 동통, 하순의 점상 출혈 등을 들 수 있다. 적극적인 항생제 투여와 G-CSF 피하 주사가 환자의 전신적 상태 향상에 도움을 줄 수 있으나 완치가 어렵기에 치과 치료시 주의가 필요하며, 구강위생관리를 철저히 잘 할 수 있도록 환자 및 보호자에게 지속적인 관심을 가지고 교육해야 할 것이다.

  • PDF

Adult Primary Myelodysplastic Syndrome: Experience from a Tertiary Care Center in Pakistan

  • Sultan, Sadia;Irfan, Syed Mohammed
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제17권3호
    • /
    • pp.1535-1537
    • /
    • 2016
  • Background: Primary myelodysplastic syndrome (MDS) is an acquired clonal disorder of myeloid progenitor cells, characterized by peripheral cytopenias in the presence of hypercellular marrow with dysplastic features. Our aim was to study the demographical and clinicopathological features of adult Pakistani patients with MDS at disease presentation. Materials and Methods: This single centre study was conducted at Liaquat National Hospital and Medical College, extending from January 2010 to December 2014. Data were retrieved from the patient archives. Results: Overall 45 patients were diagnosed at our institution with de novo MDS during the study period. There were 28 males and 17 females. Age ranged between 18 and 95 years with a mean age of $57.6{\pm}17.4years$ and median of 64 years. The male to female ratio was 1.7:1. The main presenting complaints were generalized fatigue (60%), fever (33.3%), dyspnea (15.5%), bleeding (13.3%) and weight loss (11.1%). Examination was unremarkable in 42.2% of patients. Physical examination revealed pallor in 37.7%, followed by petechial and purpuric rashes in 20%. The commonest laboratory finding was anemia (hemoglobin < 10 g/dl in 41 (91.1%) patients. Out of these, 27 (60%) patients had normocytic anemia, followed by macrocytic (22.2%) and microcytic (8.8%). Conclusions: Primary MDS in Pakistani patients demonstrates a male preponderance. The proportion of anemic patients was high in our series with predominance of normocytic anemia. However, other clinico-hematological features appear comparable to published data.

Spectrum of the WHO Classification De Novo Myelodysplastic Syndrome: Experience from Southern Pakistan

  • Sultan, Sadia;Irfan, Syed Mohammed;Jawed, Syeda Narisa
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제17권3호
    • /
    • pp.1049-1052
    • /
    • 2016
  • Background: Myelodysplastic syndrome (MDS) is a clonal disorder of hemopoeitic stem cells, characterized by infective hematopoiesis, peripheral cytopenias along with hypercellularity of marrow and marked dysplastic features. Our aim was to study the spectrum of the WHO classification in adult Pakistani patients with MDS at disease presentation. Materials and Methods: This retrospective descriptive study was conducted at Liaquat National Hospital and Medical College, extending from January 2010 to December 2014. Patient data were retrieved from the maintained archives. Results: Overall, 45 patients were diagnosed at our institution with de novo MDS during the study period. There were 28 males and 17 females. Age ranged between 18 and 95 years with a mean of $57.6{\pm}17.4years$. The male to female ratio was 1.7:1. According to the WHO classification, 53.3% had refractory cytopenia with multilineage dysplasia, 22.2% had refractory cytopenia with unilineage dysplasia, 4.4% each had refractory anemia with excess of blasts-1 and II and 15.5% had MDS unclassified. The main presenting complaints were generalized fatigue (60%), fever (33.3%), dyspnea (15.5%), bleeding (13.3%) and weight loss (11.1%). Physical examination revealed pallor in 37.7%, followed by petechial and purpuric rashes in 20% of patients. Hemoglobin was <10 g/dl in 41 (91.1%). Pancytopenia and bicytopenia were noted in 18 (40%) and 14 (31.1%) respectively. Conclusions: MDS in our patients presents at a relatively young age. Refractory c ytopenia with multilineage dysplasia was the dominant disease variant in our setting.

Pulmonary Leukocytoclastic Vasculitis as an Initial Presentation of Myelodysplastic Syndrome

  • Lee, Seung Hyun;Kim, Jae Hyung;Park, Sejin;Won, Chang Youn;Lee, Joo-Hyun;Yi, Seong Yoon;Park, Hye Kyeong;Chang, Sun Hee;Jung, Hoon;Lee, Sung-Soon;Koo, Hyeon-Kyoung
    • Tuberculosis and Respiratory Diseases
    • /
    • 제79권4호
    • /
    • pp.302-306
    • /
    • 2016
  • Systemic vasculitis involving the lung is a rare manifestation of myelodysplastic syndrome (MDS), and secondary vasculitis is considered to have poor prognosis. A 44-year-old man presented with fever and dyspnea of 1 month duration. A chest radiograph revealed bilateral multiple wedge shaped consolidations. In addition, the results of a percutaneous needle biopsy for non-resolving pneumonia were compatible with pulmonary vasculitis. Bone marrow biopsy was performed due to the persistence of unexplained anemia and the patient was diagnosed with MDS. We reported a case of secondary vasculitis presenting as non-resolving pneumonia, later diagnosed as paraneoplastic syndrome of undiagnosed MDS. The cytopenia and vasculitis improved after a short course of glucocorticoid treatment, and there was no recurrence despite the progression of underlying MDS.

Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome

  • Choi, Eun-Ji;Lee, Je-Hwan;Lee, Jung-Hee;Park, Han-Seung;Ko, Sun-Hye;Seol, Miee;Lee, Young-Shin;Kang, Young-Ah;Jeon, Mijin;Lee, Kyoo-Hyung
    • BLOOD RESEARCH
    • /
    • 제53권4호
    • /
    • pp.288-293
    • /
    • 2018
  • Background Although allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment option for myelodysplastic syndrome (MDS), a substantial number of patients experience relapse. We reviewed the clinical outcomes of patients with MDS who relapsed after allogeneic HCT. Methods Thirty patients who experienced relapse or progression after allogeneic HCT for MDS between July 2000 and May 2016 were included in this retrospective analysis. Results The median time from HCT to relapse was 6.6 (range, 0.9-136.3) months. Donor lymphocyte infusions (DLIs) were administered to four patients: one achieved complete remission (CR) and survived disease free, while three did not respond to DLI and died. Hypomethylating agents were administered to seven patients: one who had stable disease continuously received decitabine, while six died without response to treatment. Six patients received AML-like intensive chemotherapy, and three achieved CR: two underwent second HCT and one DLI. One patient receiving second HCT survived without disease, but the other two relapsed and died. Three, four, and eight patients who did not respond to intensive chemotherapy, low-dose cytarabine, and best supportive care, respectively, died. One patient who underwent second HCT following cytogenetic relapse survived disease free. Median overall survival after relapse was 4.4 months, and relapse within 6 months after HCT was associated with shorter survival. Conclusion Outcomes of MDS patients relapsing after allogeneic HCT were disappointing. Some patients could be saved using DLI or second HCT.

RUNX1 Mutations in the Leukemic Progression of Severe Congenital Neutropenia

  • Olofsen, Patricia A.;Touw, Ivo P.
    • Molecules and Cells
    • /
    • 제43권2호
    • /
    • pp.139-144
    • /
    • 2020
  • Somatic RUNX1 mutations are found in approximately 10% of patients with de novo acute myeloid leukemia (AML), but are more common in secondary forms of myelodysplastic syndrome (MDS) or AML. Particularly, this applies to MDS/AML developing from certain types of leukemia-prone inherited bone marrow failure syndromes. How these RUNX1 mutations contribute to the pathobiology of secondary MDS/AML is still unknown. This mini-review focusses on the role of RUNX1 mutations as the most common secondary leukemogenic hit in MDS/AML evolving from severe congenital neutropenia (SCN).

Neutrophil to Lymphocyte Ratio - Not an Independent Prognostic Factor in Patients with the Myelodysplastic Syndrome

  • Akinci, Sema;Silay, Kamile;Ulas, Arife;Guney, Tekin;Hacibekiroglu, Tuba;Basturk, Abdulkadir;Akinci, Muhammed Bulent;Alkan, Afra;Dilek, Imdat
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권24호
    • /
    • pp.10883-10885
    • /
    • 2015
  • Purpose: Neutrophil-to-lymphocyte ratio (NLR) was evaluated as a potential prognostic factor in patients with myelodysplastic syndrome (MDS). Materials and Methods: Between December 2009 and April 2014, 14 female (35%) and 26 male (65%) MDS patients who were followed up in our hematology clinic were included in the study for NLR during diagnosis. Division was into two groups according to the NLR, and the correlation with mortality was evaluated. The prognostic significance of NLR regarding treatment outcome was also evaluated with adjustment for known confounding risk factors. Results: The mortality rate of the patient group was 55%, and median survival was 18 months. There was no significant correlation between mortality and NLR at a median value of 1.8 (p=0.75). Thrombocytopenia was observed to increase mortality (p=0.027), and there was a significant correlation between mortality and pancytopenia (p=0.017). Conclusions: This first study of NLR and mortality did not show any significant correlation. In centres with limited access to genetic evaluation for the presence of pancytopenia and/or thrombocytopenia at the time of diagnosis, a platelet level less than $50{\times}10^9/l$ may be poor prognostic markers in MDS patients.

Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia

  • Chaudhary, Ajay K;Chaudhary, Shruti;Ghosh, Kanjaksha;Shanmukaiah, Chandrakala;Nadkarni, Anita H
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제17권3호
    • /
    • pp.1519-1529
    • /
    • 2016
  • Background: Matrix metalloproteinase -2 (gelatinase-A, Mr 72,000 type IV collagenase, MMP-2) and -9 (gelatinase-B, Mr 92,000 type IV collagenase, MMP-9) are key molecules that play roles in tumor growth, invasion, tissue remodeling, metastasis and stem-cell regulation by digesting extracellular matrix barriers. MMP-2 and -9 are well known to impact on solid cancer susceptibility, whereas, in hematological malignancies, a paucity of data is available to resolve the function of these regulatory molecules in bone marrow mononuclear cells (BM-MNCs) and stromal cells of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Objectives: The present study aimed to investigate mRNA expression and gelatinase A and B secretion from BM-MNCs in vitro and genotypic associations of MMP-2 (-1306 C/T; rs243865), MMP-9 (-1562 C/T; rs3918242), tissue inhibitor of metalloproteinase -1 (TIMP-1) (372T/C; rs4898, Exon 5) and TIMP-2 (-418G/C; rs8179090) in MDS and AML. Results: The study covered cases of confirmed MDS (n=50), AML (n=32) and healthy controls (n=110). MMP-9 mRNA expression revealed 2 fold increased expression in MDS-RAEB II and 2.5 fold in AML M-4 (60-70% blasts). Secretion of gelatinase-B also revealed the MMP-9 mRNA expression and ELISA data also supported these data. We noted that those patients having more blast crises presented with more secretion of MMP-9 and its mRNA expression. In contrast MMP-9 (-1562 C/T) showed significant polymorphic associations in MDS (p<0.02) and AML (p<0.02). MMP-9 mRNA expression of C/T and T/T genotypes were 1.5 and 2.5 fold increased in MDS and AML respectively. In AML, MMP-2 C/T and T/T genotypes showed 2.0 fold mRNA expression. Only MMP-9 (-1306 C/T) showed significant 4 fold (p<0.001) increased risk with chemical and x-ray exposed MDS, while tobacco and cigarette smokers have 3 fold (p<0.04) risk in AML. Conclusions: In view of our results, MMP-9 revealed synergistic secretion and expression in blast crises of MDS and AML with 'gene' polymorphic effects and is significantly associated with increased risk with tobacco, cigarette and environmental exposure. Release and secretion of these enzymes may influence hematopoietic cell behavior and may be important in the clinical point of view. It may offer valuable tools for diagnosis and prognosis, as well as possible targets for the treatments.

한방 치료를 통한 골수이형성증후군 치험례 2례 (Well-Managed Myelodysplastic Syndrome Patients Treated with Traditional Korean Medicine; Report of Two Cases)

  • 김준영;정진용;손창규;조정효
    • 대한한방내과학회지
    • /
    • 제37권3호
    • /
    • pp.539-547
    • /
    • 2016
  • 본 증례에서는 한방치료를 받은 두 명의 골수이형성증후군 환자를 통하여 골수이형성증후군에 대한 한방치료의 효과를 보여주고자 하였다. 골수이형성증후군은 골수의 증식과 구성 세포들의 이형성, 비효율적인 조혈을 특징으로 하는 골수의 악성 종양이다. 현재까지 골수이형성증후군에 대한 완벽한 치료법은 없으며 골수이형성증후군의 증상을 경감시키거나 급성 골수성 백혈병으로의 진행을 막는 목적으로 치료가 이뤄지고 있다. 첫 번째 환자는 1차성 골수이형성증후군 환자로 2011년 1월부터 2016년 현재까지 꾸준히 침 치료 및 한약치료를 받고 있다. 두 번째 환자는 난소암 치료를 위한 항암화학요법의 부작용으로 생긴 2차성 골수이형성증후군 환자로 2010년 10월부터 4년간 꾸준한 한약 복용 및 3번의 입원치료를 받은 환자이다. 침 치료, 한약 치료와 함께 환자들의 상태를 평가하기 위해 정기적인 혈액검사가 이루어졌다. 골수이형성증후군 진단 후 두 달에 한 번씩 수혈을 받으며 수혈 의존 경향을 보이던 첫 번째 환자는 한방치료 후 단 두 번의 수혈밖에 받지 않았고 급성골수성백혈병으로 진행하지도 않았으며 건강한 몸 상태를 유지하고 있다. 두 번째 환자 역시 꾸준한 한방치료를 통해 비교적 좋은 삶의 질을 유지하며 기본 체력 또한 많이 상승되면서 골수 이식을 받을 정도까지 몸 상태가 개선되었다. 본 증례보고는 마땅한 치료법이 없는 골수이형성증후군 환자들에게 한방 치료가 특별한 부작용 없이 환자들이 호소하는 증상을 개선하고 기본적인 체력 증진에 도움이 되며 급성 골수성 백혈병으로의 진행을 예방하는 동시에 기존의 보존적 치료법의 효과를 극대화 시키는 효과가 있음을 보여주는 증례라고 하겠다.

요통을 동반한 MDS 환자에 대한 관리 1례 (A Case Report of a Patient with Myelodysplastic Syndrome Who Has Lower Back Pain)

  • 주성희;배정한;안소연;장은경;이장훈;김영철
    • 대한한방내과학회지
    • /
    • 제39권2호
    • /
    • pp.230-236
    • /
    • 2018
  • Objectives: This case aims to describe management of a patient with myelodysplasitc syndrome who has lower back pain. Methods: A 75-year-old female patient with myelodysplasitc syndrome was hospitalized from February 28, 2018 to March 14, 2018. The patient was treated with Azacitidine at Bundangjyesaeng Hospital, and lower back pain worsened without any reason. The patient was willing to undergo traditional Korean medical treatment, and Wonyuksayuk-tang was chosen considering both hematopoiesis dysfunction and lower back pain. Results: The patient was diagnosed with myelodysplatic syndrome after bone marrow aspiration and biopsy at Bundangjyesaeng Hospital. After the Wonyuksayuk-tang treatment, platelet levels increased about 50% compared with initial blood test results. In addition, lower back pain and general weakness were slightly improved. Conclusion: It is important to manage the quality of life of patients with myelodysplastic syndrome. This case suggests that traditional Korean medicine has a beneficial effect on the management of myelodysplastic syndrome.